ADME/Tox

       
The drug discovery process is both a high cost and high risk endeavor. It has been estimated that bringing a drug candidate to market can cost in the range of $1–2 billion dollars and typically takes 12 years to complete. It is therefore no surprise that withdrawal in the later stages of this process is devastatingly expensive to the pharmaceutical industry.

An obvious improvement to these high costs and long timelines is to find ways to eliminate non-viable drug candidates from therapeutic programs much earlier in the process. This has made the ADME and toxicology stages of drug discovery a focal point for improvements by the pharmaceutical industry. Advances in ADME and toxicology studies have the potential to increase the probability of success, decrease overall costs and reduce the time to market. The introduction of new technologies for ADME and toxicology holds the potential to further accelerate such gains in efficiency.

Below are some of these newer technologies offered by Sigma® Life Science for ADME and toxicology research. One primary advance is genetically modified cell lines that improve upon, and simplify, in vitro membrane transporter research. In addition, Sigma Life Science has an extensive portfolio of reagents, consumables and labware that are tailored for ADME and toxicology research.
 



     

Model Systems:

Reagents:
 

Consumables:

Services:
 


Learning Center:

     
Biofiles: Predictive Tools for ADME and Toxicology Studies
This app highlights some of these newer technologies offered by Sigma Life Science for ADME and toxicology research. One primary advance is genetically modified cell lines that improve upon, and simplify, in vitro membrane transporter research. In addition, Sigma Life Science has an extensive portfolio of reagents, consumables and labware that are tailored for ADME and toxicology research.

Get It Free for your iPad on iTunes: